Program
Trastuzumab
Also written as “Herceptin”, “trastuzumab [Herceptin]” and “trastuzumab”.
Its studies are mostly in Breast Neoplasms · Stomach Neoplasms · Colorectal Neoplasms · Neoplasms · Urologic Neoplasms, led by 20 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 470 open or running | phase 4since Dec 13, 2010 | May 2, 2000 | none ahead |
| Novartis | 50 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizer | 31 open or running | phase 3since Feb 14, 2022 | Oct 20, 2005 | Dec 31, 2027phase 3 · NCT05253651 |
| Celltrion | 20 open or running | phase 3since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 2since Aug 31, 2007 | Aug 31, 2007 | none ahead |
| Prestige Biopharma | 20 open or running | phase 3since Dec 29, 2016 | Dec 29, 2016 | none ahead |
| Sanofi | 20 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sarah Cannon Research Institute | 21 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Tanvex BioPharma USA | 20 open or running | phase 3since Jun 1, 2018 | Jun 1, 2018 | none ahead |
| aryogen-pharmed-co | 10 open or running | phase 3since Nov 21, 2017 | Nov 21, 2017 | none ahead |
| Biocad | 10 open or running | phase 3since Jan 7, 2013 | Jan 7, 2013 | none ahead |
| cogent-biosciences-inc | 10 open or running | phase 1since Sep 14, 2018 | Sep 14, 2018 | none ahead |
| incepta-pharmaceuticals-ltd | 10 open or running | phase 1since Jan 12, 2025 | Jan 12, 2025 | none ahead |
| Jiangsu HengRui Medicine | 11 open or running | phase 3since Aug 14, 2026 | Aug 14, 2026 | Feb 28, 2030phase 3 · NCT07779538 |
| meiji-seika-pharma-co-ltd | 10 open or running | phase 1since Mar 27, 2014 | Mar 27, 2014 | none ahead |
| Merck | 10 open or running | phase 2since May 27, 2008 | May 27, 2008 | none ahead |
| NovoCure | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| orano-med-llc | 10 open or running | phase 1since Jun 27, 2011 | Jun 27, 2011 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 1since Mar 1, 2023 | Mar 1, 2023 | none ahead |
| Viatris | 10 open or running | phase 1since Oct 29, 2015 | Oct 29, 2015 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo, medivation-llc-a-wholly-owned-subsidiary-of-pfizer-inc, AbbVie, Zai Lab, nippon-kayaku-co-ltd, mds-pharma-services, mylan-gmbh and Dong-A Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Dec 1, 2008.
- Apr 20, 2016Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02748213 · 225 enrolled · Australia, Brazil, Canada and more
- Dec 29, 2016Prestige Biopharma's first study: phase 3 study in Breast NeoplasmsNew to Prestige BiopharmaPrestige Biopharma · NCT03013504 · 503 enrolled · Belarus, Bulgaria, Estonia and more
- Nov 21, 2017aryogen-pharmed-co's first study: phase 3 study in Breast NeoplasmsNew to aryogen-pharmed-coaryogen-pharmed-co · NCT03425656 · 108 enrolled · Iran, Islamic Republic of
- Dec 12, 2017Phase 2 study in Breast NeoplasmsSarah Cannon Research Institute · NCT03379428 · 34 enrolled · United States
- Jun 1, 2018Tanvex BioPharma USA's first study: phase 3 study in Breast NeoplasmsNew to Tanvex BioPharma USATanvex BioPharma USA · NCT03556358 · 809 enrolled · Belarus, Chile, Georgia and more
- Sep 14, 2018cogent-biosciences-inc's first study: phase 1 study in Breast NeoplasmsNew to cogent-biosciences-inccogent-biosciences-inc · NCT03680560 · 6 enrolled · United States
- Dec 13, 2018Phase 1 study in Healthy VolunteersPrestige Biopharma · NCT03776240 · 105 enrolled · Australia
- Sep 20, 2019Phase 3 study in Breast NeoplasmsTanvex BioPharma USA · NCT04109391 · 338 enrolled · Belarus, Chile, Georgia and more
- Feb 20, 2020NovoCure's first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
- Feb 14, 2022Phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651 · 400 enrolled · United States, Argentina, Australia and more
- Mar 1, 2023Sino Biopharmaceutical's first study: phase 1 study in Breast NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05765357 · 89 enrolled · China
- Jan 12, 2025incepta-pharmaceuticals-ltd's first study: phase 1 study in Breast NeoplasmsNew to incepta-pharmaceuticals-ltdincepta-pharmaceuticals-ltd · NCT06886659 · 80 enrolled · Bangladesh
- Oct 6, 2025Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT07214766 · 331 enrolled · United States
- Aug 14, 2026Jiangsu HengRui Medicine's first study: phase 3 study in Ovarian NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07779538 · 420 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651
- Feb 28, 2030Primary completion: phase 3 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT07779538
TargetBeta
“A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2)”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07779538Ovarian Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Feb 28, 2030 | 420 |
| NCT07214766Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Jul 3, 2026 | 331 |
| NCT06886659Breast Neoplasms · Bangladesh | 1 | Completed | incepta-pharmaceuticals-ltd | Dec 28, 2024 | 80 |
| NCT05765357Breast Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Oct 27, 2017 | 89 |
| NCT05253651Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Dec 31, 2027 | 400 |
| NCT04281576Stomach Neoplasms · Hong Kong | – | Completed | NovoCure | Jun 7, 2024 | 28 |
| NCT04109391Breast Neoplasms · Belarus, Chile, Georgia and more | 3 | Completed | Tanvex BioPharma USA | Dec 25, 2021 | 338 |
| NCT03776240Healthy Volunteers · Australia | 1 | Completed | Prestige Biopharma | Aug 19, 2019 | 105 |
| NCT03680560Breast Neoplasms · United States | 1 | Terminated | cogent-biosciences-inc | Mar 12, 2020 | 6 |
| NCT03556358Breast Neoplasms · Belarus, Chile, Georgia and more | 3 | Completed | Tanvex BioPharma USA | Nov 27, 2020 | 809 |
| NCT03379428Breast Neoplasms · United States | 2 | Active, not recruiting | Sarah Cannon Research Institute | Jan 2025 | 34 |
| NCT03425656Breast Neoplasms · Iran, Islamic Republic of | 3 | Completed | aryogen-pharmed-co | Mar 6, 2018 | 108 |
| NCT03013504Breast Neoplasms · Belarus, Bulgaria, Estonia and more | 3 | Completed | Prestige Biopharma | Apr 19, 2019 | 503 |
| NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more | 2 | Completed | Hoffmann-La Roche | Mar 2006 | 225 |
| NCT02721641Neoplasms · Australia, Belgium, China and more | 3 | Completed | Hoffmann-La Roche | Feb 2015 | 69 |
| NCT02665637Healthy Volunteers · United States | 1 | Completed | Celltrion | Apr 2016 | 70 |
| NCT02594761Healthy | 1 | Completed | Viatris | Feb 2014 | 132 |
| NCT02536339Breast Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 1, 2019 | 40 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Jun 24, 2021 | 110 |
| NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more | 3 | Completed | Hoffmann-La Roche | Feb 22, 2019 | 418 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02213042Breast Neoplasms · United States, Argentina, Austria and more | 2 | Terminated | Novartis | Jun 4, 2020 | 42 |
| NCT02194166Breast Neoplasms · Belarus, Kazakhstan | 3 | Completed | Hoffmann-La Roche | Jul 12, 2018 | 90 |
| NCT02162667HER2-positive Carcinoma of Breast · Argentina, Belarus, Bosnia and Herzegovina and more | 3 | Completed | Celltrion | May 26, 2016 | 562 |
| NCT02132949Breast Neoplasms · United States, Canada, Denmark and more | 2 | Completed | Hoffmann-La Roche | Mar 3, 2016 | 401 |
| NCT02100917Neoplasms · Japan | 1 | Completed | meiji-seika-pharma-co-ltd | May 2014 | 70 |
| NCT02091141Neoplasms · United States | 2 | Completed | Hoffmann-La Roche | May 24, 2023 | 673 |
| NCT02040935Breast Neoplasms · Netherlands | 3 | Completed | Hoffmann-La Roche | Sep 14, 2018 | 128 |
| NCT02019277Breast Neoplasms · Australia | 3 | Completed | Hoffmann-La Roche | Nov 4, 2016 | 50 |
| NCT02006667Urologic Neoplasms · Germany | 2 | Completed | Hoffmann-La Roche | Jan 2010 | 13 |
| NCT02005484Stomach Neoplasms · Austria, Germany | 2 | Terminated | Hoffmann-La Roche | Feb 2008 | 6 |
| NCT02015676Breast Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Sep 2009 | 69 |
| NCT02013765Urologic Neoplasms · Germany | 2 | Terminated | Hoffmann-La Roche | Jan 2010 | 5 |
| NCT01998906Breast Neoplasms · Austria, Germany, Italy and more | 3 | Completed | Hoffmann-La Roche | Jul 2012 | 330 |
| NCT01964391Breast Neoplasms · Algeria, Morocco, Saudi Arabia and more | 3 | Completed | Hoffmann-La Roche | Dec 22, 2016 | 174 |
| NCT01940497Breast Neoplasms · Italy | 3 | Completed | Hoffmann-La Roche | Apr 5, 2016 | 240 |
| NCT01928615Breast Neoplasms · Austria | 2 | Terminated | Hoffmann-La Roche | Oct 2013 | 2 |
| NCT01926886Breast Neoplasms · Belgium, Israel | 3 | Completed | Hoffmann-La Roche | Sep 4, 2015 | 102 |
| NCT01810393Breast Neoplasms · France | 3 | Completed | Hoffmann-La Roche | Jul 17, 2019 | 114 |
| NCT01764022Breast Neoplasms · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Mar 2015 | 225 |
| NCT01748773Stomach Neoplasms · Turkey | 2 | Completed | Hoffmann-La Roche | Aug 21, 2015 | 34 |
| NCT01566721Breast Neoplasms · Albania, Algeria, Argentina and more | 3 | Completed | Hoffmann-La Roche | Mar 10, 2015 | 2,577 |
| NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 296 |
| NCT01401166Breast Neoplasms · Canada, Denmark, France and more | 2 | Completed | Hoffmann-La Roche | May 2013 | 488 |
| NCT01384253Breast Neoplasms · United States | 1 | Completed | orano-med-llc | Oct 2015 | 18 |
| NCT01363986Breast Neoplasms · Italy | 2 | Terminated | Hoffmann-La Roche | Jun 2012 | 3 |
| NCT01344863Healthy Volunteer · New Zealand | 1 | Completed | Hoffmann-La Roche | Jan 2012 | 119 |
| NCT01301729Breast Neoplasms · China | 4 | Completed | Hoffmann-La Roche | Jul 2014 | 32 |
| NCT01290718Breast Neoplasms · Taiwan | 2 | Terminated | Hoffmann-La Roche | Dec 2012 | 4 |
| NCT01260194Stomach Neoplasms · India | 4 | Terminated | Hoffmann-La Roche | Jan 2015 | 4 |
| NCT01160211Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Novartis | Mar 11, 2016 | 369 |
| NCT01137994Breast Neoplasms | 2 | Withdrawn | GlaxoSmithKline | Dec 2016 | 0 |
| NCT01130337Stomach Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Jun 2014 | 36 |
| NCT01041404Stomach Neoplasms · Australia, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Jun 2010 | 584 |
| NCT00964704Breast Neoplasms | 2 | Withdrawn | Hoffmann-La Roche | Aug 2013 | 0 |
| NCT00950300Breast Neoplasms · Argentina, Brazil, Canada and more | 3 | Completed | Hoffmann-La Roche | Jul 12, 2011 | 596 |
| NCT00927589Solid Cancers · United States | 1 | Completed | Hoffmann-La Roche | Feb 2013 | 59 |
| NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more | 2 | Completed | Hoffmann-La Roche | Feb 18, 2013 | 33 |
| NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more | 2 | Completed | Hoffmann-La Roche | Dec 2015 | 88 |
| NCT00800436Breast Neoplasms · Australia, New Zealand | 1 | Completed | Hoffmann-La Roche | Oct 2009 | 66 |
How it is read
Names in the registry
- “Trastuzumab”, 36 entries
- “Herceptin”, 13 entries
- “trastuzumab [Herceptin]”, 11 entries
- “trastuzumab”, 9 entries
- “HD201”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 63 studies
- Stomach Neoplasms, 7 studies
- Colorectal Neoplasms, 2 studies
- Neoplasms, 2 studies
- Urologic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.